TGF-β Signaling in Cancer Metastasis: A Dual-Role Player in Progression and Therapy Resistance
노바스템
2024-04-18
조회수 213
This review by Feng Xie and colleagues focuses on the dual roles of Transforming Growth Factor-beta (TGF-β) signaling in cancer progression, particularly in metastasis. TGF-β acts as a tumor suppressor in early cancer stages but paradoxically promotes invasion and metastasis in advanced stages. The signaling involves complex interactions with other pathways, including Hippo, Wnt, EGFR/RAS, and PI3K/AKT, enhancing its multifaceted roles in cancer dynamics. Importantly, the review discusses how cross-talk between these pathways contributes to a deeper understanding of TGF-β's role in cancer, offering insights into therapeutic targets. TGF-β's ability to induce epithelial-mesenchymal transition (EMT) is highlighted as a key mechanism in promoting metastasis, where it increases the expression of mesenchymal markers and decreases epithelial markers, facilitating cancer cell migration and invasion.
Similar to its role in cancer, TGF-β signaling's complex nature could be leveraged in designing Novastem’s stem cell therapies. For conditions requiring modulation of cellular growth and differentiation, such as fibrotic diseases or certain cancers, understanding TGF-β's dual role could improve therapeutic strategies. These might involve using stem cell therapies to modulate similar pathways, potentially enhancing tissue regeneration while avoiding undesirable fibrosis or aiding in the treatment of cancers by regulating the tumor microenvironment.
Dual Role of TGF-β: Acts as a tumor suppressor and a promoter in cancer, which involves transitioning from inhibiting to promoting cell proliferation and invasion.
Cross-talk with Other Pathways: Enhances the complexity of TGF-β roles in cancer, suggesting potential multi-target therapeutic approaches.
EMT Induction: Key process driven by TGF-β in cancer metastasis, providing a target for interventions aiming to inhibit metastatic spread.
This review by Feng Xie and colleagues focuses on the dual roles of Transforming Growth Factor-beta (TGF-β) signaling in cancer progression, particularly in metastasis. TGF-β acts as a tumor suppressor in early cancer stages but paradoxically promotes invasion and metastasis in advanced stages. The signaling involves complex interactions with other pathways, including Hippo, Wnt, EGFR/RAS, and PI3K/AKT, enhancing its multifaceted roles in cancer dynamics. Importantly, the review discusses how cross-talk between these pathways contributes to a deeper understanding of TGF-β's role in cancer, offering insights into therapeutic targets. TGF-β's ability to induce epithelial-mesenchymal transition (EMT) is highlighted as a key mechanism in promoting metastasis, where it increases the expression of mesenchymal markers and decreases epithelial markers, facilitating cancer cell migration and invasion.
Similar to its role in cancer, TGF-β signaling's complex nature could be leveraged in designing Novastem’s stem cell therapies. For conditions requiring modulation of cellular growth and differentiation, such as fibrotic diseases or certain cancers, understanding TGF-β's dual role could improve therapeutic strategies. These might involve using stem cell therapies to modulate similar pathways, potentially enhancing tissue regeneration while avoiding undesirable fibrosis or aiding in the treatment of cancers by regulating the tumor microenvironment.
#TGFβ #CancerMetastasis #EMT #StemCellTherapy #Novastem #TherapeuticTargeting #DualRole #PathwayCrossTalk